Public offering

COINBASE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Coinbase Global, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, October 1, 2022
Class Action Lawsuit, Professional Services, Legal, The Wall Street Journal, Policy, Twitter, Risk, Bankruptcy, Company, Compliance, News, Goldman Sachs, P.C, Public offering, Person, Letter, Bloomberg, District, Lists of schools in England, Defendant, Armstrong, Jeanne Eagels, Court, NASDAQ, Telephone, District court, SEC, Prospectus, Register, Security (finance), Cryptocurrency, Coinbase

Throughout the Class Period, Defendants continued to tout Coinbase’s strength as a crypto custodian and commitment to regulatory compliance, in addition to denying that Coinbase engaged in any proprietary trading. For example, during a Goldman Sachs financial services conference on December 7, 2021, Defendant Emilie Choi—the Company’s President and Chief Operating Officer—emphasized the Company’s firm policy against proprietary trading, explaining: “I mean I think it’s kind of obvious in a way. It’s just people don’t want to feel like you’re trading -- institutions don’t want to feel like you’re going to be trading against them. And so we’ve always had a clear line about not doing that.”

Key Points: 
  • Investors have until October 3, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Coinbases common stock trades in the United States on the NASDAQ under the ticker symbol COIN.
  • The Class Period begins on April 14, 2021, to coincide with the Companys initial listing of common stock on the NASDAQ (the Direct Listing).
  • However, the truth began to emerge on May 10, 2022, when Coinbase filed its first quarter 2022 financial report with the SEC.

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Coinbase Global, Inc. With Expanded Class Period

Retrieved on: 
Wednesday, September 28, 2022
Class Action Lawsuit, Professional Services, Legal, The Wall Street Journal, Policy, Twitter, Risk, Bankruptcy, Company, Compliance, News, Goldman Sachs, Public offering, Letter, LLP, Bloomberg, District, Lists of schools in England, Defendant, Armstrong, Fraud, NASDAQ, District court, SEC, Prospectus, Register, Lead, Security (finance), Cryptocurrency, Coinbase

There is another related class action case pending against Coinbase in the United States District Court for the District of New Jersey.

Key Points: 
  • There is another related class action case pending against Coinbase in the United States District Court for the District of New Jersey.
  • The Class Period begins on April 14, 2021, to coincide with the Companys initial listing of common stock on the NASDAQ (the Direct Listing).
  • Kessler Topaz Meltzer & Check, LLP encourages Coinbase investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.

Patrimonium Urban Opportunity AG starts trading in the SME Main Market of BX Swiss

Retrieved on: 
Monday, July 18, 2022
BX Swiss, Acquisition, CEO, CHF, Ticker, ISIN, Public offering, Real estate

Today, the shares of Swiss real estate company Patrimonium Urban Opportunity AG are traded for the first time on BX Swiss.

Key Points: 
  • Today, the shares of Swiss real estate company Patrimonium Urban Opportunity AG are traded for the first time on BX Swiss.
  • As of today, July 18th, 2022, the shares of Patrimonium Urban Opportunity AG are traded on BX Swiss (ISIN: CH 1141117965 / Valoren-Nr.
  • With the Direct Listing of Patrimonium Urban Opportunity AG, a total of 38101'266 registered shares with a nominal value of CHF 1.00 each will be listed.
  • We are proud to welcome Patrimonium Urban Opportunity AG to BX Swiss and to include them in our main exchange segment, the SME Main Market, emphasizes Lucas Bruggeman, CEO of BX Swiss AG.

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Retrieved on: 
Monday, June 27, 2022
SEDAR, FOR, Offering, Securities Act of 1933, Research, Vehicle registration plates of the Netherlands, GLOBE, AGN, Indian stock exchange, Exercise, Sale, Company, Disease, CSE, Warrant, Supplement, NOT, Public offering, Regulation, Canadian Securities Exchange, Time, Security (finance), Unit, Unit

VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce the price of its previously announced marketed public offering of units of the Company (the “Units” or the “Offered Securities”) with Research Capital Corporation as the sole agent and sole bookrunner (the “Agent”), in each of the provinces of Canada (other than Quebec) (the “Offering”). Pursuant to the Offering, the Company intends to issue up to 533,333 Units at a price of $3.75 per Unit for aggregate gross proceeds of up to $2,000,000.

Key Points: 
  • Pursuant to the Offering, the Company intends to issue up to 533,333 Units at a price of $3.75 per Unit for aggregate gross proceeds of up to $2,000,000.
  • The net proceeds from the Offering of the Units will be used to fund research and development programs, general and administrative expenses and for working capital purposes.
  • The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Algernon Pharmaceuticals Announces Public Offering of Units

Retrieved on: 
Wednesday, June 15, 2022
Time, Degenerative disease, Indian stock exchange, SEDAR, Company, Research, FOR, NOT, Ifenprodil, CSE, Disease, Exercise, Vehicle registration plates of the Netherlands, Securities Act of 1933, Regulation, Sale, Supplement, Canadian Securities Exchange, Public offering, AGN, Offering, GLOBE, Security (finance), Warrant, Unit

VANCOUVER, British Columbia, June 15, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce that it is undertaking a marketed public offering of units of the Company (the “Units” or the “Offered Securities”) with Research Capital Corporation as the sole agent and sole bookrunner (the “Agent”), in each of the provinces of Canada (other than Quebec) (the “Offering”). The size of the Offering and price of the Units will be determined in the context of the market.

Key Points: 
  • The size of the Offering and price of the Units will be determined in the context of the market.
  • The net proceeds from the Offering of the Units will be used to fund research and development programs, general and administrative expenses and for working capital purposes.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
  • Algernon has filed intellectual property rights globally for Ifenprodil for the treatment of respiratory diseases.

Haute Capital Partners AG starts trading in the SME Main Market of BX Swiss

Retrieved on: 
Tuesday, May 24, 2022
Investment, Public offering, CHF, BX Swiss, Growth, ISIN, CEO, Fashion, Bank

Today, the shares of investment company Haute Capital Partners are traded for the first time on BX Swiss.

Key Points: 
  • Today, the shares of investment company Haute Capital Partners are traded for the first time on BX Swiss.
  • As of today, May 23rd, 2022, the shares of Haute Capital Partners AG are traded on BX Swiss (ISIN: CH1115678950 / Valoren-Nr.
  • Therefore an 'HAUTE' share offers high potential for solid performance" says Thibault Leroy Brki, Founder and Managing Director of Haute Capital Partners.
  • "We are pleased and proud to welcome Haute Capital Partners AG to BX Swiss and to include them in our main exchange segment, the SME Main Market" emphasizes Lucas Bruggeman, CEO of BX Swiss AG.

NorthWest Healthcare Properties REIT Announces $165 Million Equity Financing

Retrieved on: 
Wednesday, March 23, 2022
Offering, Exercise, Risk, Sale, WIRE, Public, RBC Capital Markets, Compliance, Toronto Stock Exchange, Ownership, SEDAR, Hospital, REIT, CEO, TSX, Private, Private placement, Person, GLOBE, NOT, News, Public offering, NEWS, FOR, Unit, Scotiabank, Security (finance), Points of the compass

TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- NorthWest Healthcare Properties Real Estate Investment Trust (TSX: NWH.UN) (“NorthWest” or the “REIT”) announced today a public offering, on a "bought deal" basis, of 10,870,000 trust units (the “Units”) at a price of $13.80 per Unit (the “Offering Price”) representing gross proceeds of approximately $150 million (the "Public Offering"). The Public Offering is being made through a syndicate of underwriters co-led by Scotiabank and RBC Capital Markets.

Key Points: 
  • The Public Offering is being made through a syndicate of underwriters co-led by Scotiabank and RBC Capital Markets.
  • NWVP currently holds an approximate 13.1% interest in NorthWest and is wholly-owned by Paul Dalla Lana, Chairman and CEO of the REIT.
  • NorthWest Healthcare Properties Real Estate Investment Trust (TSX:NWH.UN) is an unincorporated, open-ended real estate investment trust established under the laws of the Province of Ontario.
  • Accordingly, this news release does not constitute an offer for sale of securities in the United States.

GelStat Provides Corporate Update on Capital Restructuring

Retrieved on: 
Tuesday, March 8, 2022
OTC, Annual report, Forward-looking statement, Migraine, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, News, Growth, Company, Securities Act of 1933, Public offering, Marketing, Public, GSAC, Freedom, GLOBE, Pharmaceutical industry, Security (finance)

GelStat currently has approximately 618 million shares of common stock outstanding, which is an increase from approximately 524 million shares of common stock outstanding prior to commencing its Public Offering.

Key Points: 
  • GelStat currently has approximately 618 million shares of common stock outstanding, which is an increase from approximately 524 million shares of common stock outstanding prior to commencing its Public Offering.
  • In addition, the Companys Chief Executive Officer and certain members of the GelStat Board of Directors have made purchases of the Companys common stock.
  • We are continuing to make great progress in our efforts to rebuild GelStat for the future," said Company CEO Javier Acosta.
  • GelStat expects to provide more regular corporate updates to the market over the coming weeks and months.

DGAP-News: Successful approval of the securities prospectus

Retrieved on: 
Thursday, December 2, 2021
Securities Act of 1933, Börse München, CEO, NOT, Time, Industry, Judgement of the German Federal Court of Justice on Google's autocomplete function, LAWS, News, Muscle atrophy, Health, Public offering, Federal Financial Supervisory Authority, DGAP, Athlete, ESA, ISS, Regulation, Bone loss, AMERICA, EMS, Center, Dodge Powerbox, Lawyer, Knowledge, COUNTRY, TO, THE, Federal republic, Growth, Security (finance), Cryptocurrency

The securities prospectus has been reviewed by the German Federal Financial Supervisory Authority ("BaFin") for completeness, coherence and comprehensibility and has already been approved.

Key Points: 
  • The securities prospectus has been reviewed by the German Federal Financial Supervisory Authority ("BaFin") for completeness, coherence and comprehensibility and has already been approved.
  • The securities prospectus is available for download on the issuer's homepage (www.ems.ag) within the section "Public Offering".
  • It is noted that an approval of the securities prospectus by BaFin is not to be construed as an endorsement of the relevant securities.
  • The securities mentioned in this publication are, and will be, registered neither under the U.S. Securities Act of 1933 (the "Securities Act") nor with any securities regulatory authority of any individual states of the United States of America.

EQS-News: Investment company RealUnit Schweiz AG starts trading in the SME Main Market of BX Swiss

Retrieved on: 
Monday, November 29, 2021
CEO, SME, Ticker, BX Swiss, ISIN, CHF, Public offering, Ownership, Bank

Today, the shares of investment company RealUnit Schweiz AGare traded for the first time on BX Swiss.

Key Points: 
  • Today, the shares of investment company RealUnit Schweiz AGare traded for the first time on BX Swiss.
  • As of today, November 29th, 2021, the shares of RealUnit Schweiz AG are traded on BX Swiss (ISIN: CH1129911108 / Valoren-Nr.
  • Swiss investments and the direct ownership of tangible assets are a focus of the investment activities of RealUnit Schweiz AG.
  • "We are proud to welcome RealUnit Schweiz AG, another investment company to BX Swiss," emphasized Lucas Bruggeman, CEO of BX Swiss AG.